Jane E Johnson
Overview
Explore the profile of Jane E Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
5781
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Myers B, Brayer K, Paez-Beltran L, Villicana E, Keith M, Suzuki H, et al.
Nat Commun
. 2024 Nov;
15(1):10363.
PMID: 39609428
Glioblastomas (GBMs) are highly aggressive, infiltrative, and heterogeneous brain tumors driven by complex genetic alterations. The basic-helix-loop-helix (bHLH) transcription factors ASCL1 and OLIG2 are dynamically co-expressed in GBMs; however, their...
2.
Martin-Vega A, Earnest S, Augustyn A, Wichaidit C, Girard L, Peyton M, et al.
Mol Cancer Ther
. 2024 Sep;
23(12):1789-1800.
PMID: 39295275
The transcription factor achaete-scute complexhomolog 1 (ASCL1) is a lineage oncogene that is central in growth and survival of the majority of small cell lung cancers and neuroendocrine (NE) non-small...
3.
Rodarte K, Nir Heyman S, Guo L, Flores L, Savage T, Villarreal J, et al.
Cancer Res
. 2024 Sep;
84(21):3522-3537.
PMID: 39264686
Most patients with prostate adenocarcinoma develop resistance to therapies targeting the androgen receptor (AR). Consequently, a portion of these patients develop AR-independent neuroendocrine (NE) prostate cancer (NEPC), a rapidly progressing...
4.
Myers B, Brayer K, Paez-Beltran L, Keith M, Suzuki H, Newville J, et al.
bioRxiv
. 2023 Oct;
PMID: 37873200
Glioblastomas (GBMs) are highly aggressive, infiltrative, and heterogeneous brain tumors driven by complex driver mutations and glioma stem cells (GSCs). The neurodevelopmental transcription factors ASCL1 and OLIG2 are co-expressed in...
5.
Martin-Vega A, Earnest S, Augustyn A, Wichaidit C, Gazdar A, Girard L, et al.
bioRxiv
. 2023 Jul;
PMID: 37398419
The transcription factor achaete-scute complex homolog 1 (ASCL1) is a lineage oncogene that is central for the growth and survival of small cell lung cancers (SCLC) and neuroendocrine non-small cell...
6.
Pongor L, Tlemsani C, Elloumi F, Arakawa Y, Jo U, Gross J, et al.
iScience
. 2022 Nov;
25(11):105338.
PMID: 36325065
DNA methylation is a key regulator of gene expression and a clinical therapeutic predictor. We examined global DNA methylation beyond the generally used promoter areas in human small cell lung...
7.
Kelenis D, Rodarte K, Kollipara R, Pozo K, Pal Choudhuri S, Spainhower K, et al.
Cancer Res
. 2022 Jun;
82(17):3058-3073.
PMID: 35748745
Significance: The identification of KPNB1 as a nuclear import receptor for lineage-defining transcription factors in SCLC reveals a viable therapeutic strategy for cancer treatment.
8.
Pozo K, Kollipara R, Kelenis D, Rodarte K, Ullrich M, Zhang X, et al.
iScience
. 2021 Sep;
24(9):102953.
PMID: 34466783
Lineage-defining transcription factors (LTFs) play key roles in small-cell lung cancer (SCLC) pathophysiology. Delineating the LTF-regulated genes operative in SCLC could provide a road map to identify SCLC dependencies. We...
9.
Olsen R, Ireland A, Kastner D, Groves S, Spainhower K, Pozo K, et al.
Genes Dev
. 2021 May;
35(11-12):847-869.
PMID: 34016693
ASCL1 is a neuroendocrine lineage-specific oncogenic driver of small cell lung cancer (SCLC), highly expressed in a significant fraction of tumors. However, ∼25% of human SCLC are ASCL1-low and associated...
10.
Cai L, Liu H, Huang F, Fujimoto J, Girard L, Chen J, et al.
Commun Biol
. 2021 Mar;
4(1):314.
PMID: 33750914
Small cell lung cancer (SCLC) is classified as a high-grade neuroendocrine (NE) tumor, but a subset of SCLC has been termed "variant" due to the loss of NE characteristics. In...